Fisher & Paykel Healthcare has warned of potential cost increases in the 2026 financial year due to the introduction of new tariffs in the US.
The company, which manufactures approximately 45% of its volume in Mexico and 55% in New Zealand, said that around 60% of its US volumes are supplied from its Mexico facilities.
The US recently announced a 25% tariff on products imported from Mexico and Canada, and a 10% tariff on products imported from China.
However, Fisher & Paykel does not anticipate a material impact on its net profit after tax for the 2025 financial year.
The company said it would provide an update on the outlook for the 2026 financial year and the timeframe to return to its gross margin target at its full-year results in May.
See more
